Mark A. Pirner
Abbott Laboratories
5 Papers
72 Citations
Mark A. Pirner is an academic researcher from Abbott Laboratories. The author has contributed to research in topics: Placebo & Sibutramine. The author has an hindex of 3, co-authored 3 publications.
Chat about Author
Papers
•Journal Article
Effects of Sibutramine Treatment in Obese Adolescents
Robert I. Berkowitz,Ken Fujioka,Stephen R. Daniels,Alison G. Hoppin,Stanford Owen,Arlette C. Perry,Melinda S. Sothern,Cheryl L. Renz,Mark A. Pirner,Julia K. Walch,Olga Jasinsky,Ann C. Hewkin,Vicky A. Blakesley +12 more
TL;DR: Sibutramine plus behavioral therapy for 1 year can reduce weight and improve metabolic risk factors in some very obese adolescents and is well tolerated; however, increases in mean blood pressure and pulse rate have been reported in some adults.
86
•Journal Article
Effects of sibutramine treatment in obese adolescents : A randomized trial. Commentary
William H. Dietz,Robert I. Berkowitz,Ken Fujioka,Stephen R. Daniels,Alison G. Hoppin,Stanford Owen,Arlette C. Perry,Melinda S. Sothern,Cheryl L. Renz,Mark A. Pirner,Julia K. Walch,Olga Jasinsky,Ann C. Hewkin,Vicky A. Blakesley +13 more
TL;DR: Sibutramine added to a behavior therapy program reduced BMI and body weight more than placebo and improved the profile of several metabolic risk factors in obese adolescents.
83
94-LB: A Phase 1, Double-Blind, Placebo-Controlled Multiple Escalating Dose Study of RGT-075 Novel Small-Molecule Oral GLP-1 Receptor Agonist in Adults with Type 2 Diabetes
TL;DR: A Phase 1 multiple-ascending dose study of RGT-075 in adults with type 2 diabetes (T2DM) up to 28 days was safe and QD dosing showed promising exploratory efficacy trends despite high baseline variability and short treatment duration.
2
724-P: A First-in-Human Study of RGT-075, a Novel, Orally Bioavailable, Small-Molecule GLP-1 Receptor Agonist, in Healthy Adult Subjects
TL;DR: Overall, single RGT-075 doses between 15-280 mg were safe and well-tolerated in healthy volunteers, and further clinical development of R GT-075 as a once-daily, oral therapy for T2DM is underway.
1
Effects of Sibutramine Treatment in Obese Adolescents: A Randomized Trial
Robert I. Berkowitz,Ken Fujioka,Stephen R. Daniels,Alison G. Hoppin,Stanford Owen,Arlette C. Perry,Melinda S. Sothern,Cheryl L. Renz,Mark A. Pirner,Julia K. Walch,Olga Jasinsky,Ann C. Hewkin,Vicky A. Blakesley +12 more
TL;DR: Sibutramine was shown to reduce weight more than placebo in obese adolescents who were receiving a behavior therapy program in a randomized, 3:1 randomized, double-blind trial.